J&J (JNJ) announced positive data from the phase III ICONIC-TOTAL study evaluating its investigational oral peptide, icotrokinra, for the treatment of plaque psoriasis (PsO) in patients with at least moderate severity affecting sensitive areas.The study met its primary endpoint – 57% of patients treated with the once-daily drug for 16 weeks achieved significant skin clearance compared to 6% of those who received placebo. This was measured using the Investigator’s Global Assessment (IGA), a clinical measure ...